Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Myelin Repair Foundation (MRF) has partnered with Endece Neural to advance the development of myelin regeneration drug candidates for Multiple Sclerosis (MS) patients through pre-clinical studies and into Phase I clinical studies.
Subscribe to our email newsletter
Through the collaboration, the newly launched MRF Translational Medicine Center will determine the myelin regenerating capabilities of proprietary small molecule compounds from Endece Neural.
The aim of the MRF Translational Medicine Center is to advance potential myelin repair treatment targets toward commercialization to benefit MS patients.
MRF Drug Discovery and Research Operations vice president Jay Tung said by integrating Endece’s innovative approach to remyelination and the resources available at the MRF Translational Medicine Center, they can advance progress towards developing new MS treatments for patients.
Endece Neural is a privately held neurological drug development company, and MRF is a non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for MS.